[CAS NO. 74-79-3] L-Arginine

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [74-79-3]

Catalog

HY-N0455

Brand

MCE

CAS

74-79-3

DESCRIPTION [74-79-3]

Overview

MDL	MFCD00002635
Molecular Weight	174.20
Molecular Formula	C6H14N4O2
SMILES	N[C@@H](CCCNC(N)=N)C(O)=O

For research use only. We do not sell to patients.

5 Publications Citing Use of MCE

Summary

L-Arginine ((S)-(+)-Arginine) is the substrate for the endothelial nitric oxide synthase (eNOS) to generate NO. L-Arginine is transported into vascular smooth muscle cells by the cationic amino acid transporter family of proteins where it is metabolized to nitric oxide (NO), polyamines, or L-proline ^[1] ^[2] .

IC50 & Target

Microbial Metabolite

Human Endogenous Metabolite

eNOS

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00718510	University of Alberta\|Alberta Health services	Schizophrenia	September 2009	Not Applicable
NCT03321292	Ain Shams University	Intrauterine Growth Restriction Asymmetrical	October 15, 2017	Not Applicable
NCT00469846	Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes\|University of Pennsylvania\|Bill and Melinda Gates Foundation	Pre-Eclampsia	January 2001	Phase 2
NCT00408577	IRCCS San Raffaele	Cardiovascular Disease	November 2004	Phase 3
NCT02455960	Phramongkutklao College of Medicine and Hospital	Contrast Induced AKI	September 2014	Phase 4
NCT02869204	Jens Rikardt Andersen\|Rigshospitalet, Denmark\|University of Copenhagen	Wound Infection and Wound Healing	September 2016	Not Applicable
NCT01413815	Universitätsklinikum Hamburg-Eppendorf	Cardiovascular Complication	October 2010	Not Applicable
NCT00677339	Menzies School of Health Research\|National Institute of Health Research and Development, Ministry of Health Republic of Indonesia\|Australian National University	Smear Positive Pulmonary Tuberculosis	June 2008	Phase 3
NCT00137124	University of Erlangen-Nürnberg Medical School	Essential Hypertension	May 2006	Phase 2\|Phase 3
NCT04054973	University of Massachusetts, Worcester	Schizo Affective Disorder\|Schizophrenia	September 11, 2019	Phase 2
NCT02117206	University Hospital, Strasbourg, France	Skeletal Muscle Ischemia\|Severe Lower Limb Ischemia\|Mitochondrial Dysfunction	November 2005	Phase 4
NCT05029778	Hospital Civil de Guadalajara	Fetal Growth Retardation	October 20, 2021	Phase 4
NCT04631536	Lebanese American University Medical Center	Covid19	January 10, 2021	Phase 3
NCT00848302	The Cleveland Clinic	Endothelial Dysfunction	September 2009	Early Phase 1
NCT00856817	Radboud University Medical Center\|Dutch Diabetes Research Foundation	Atherosclerotic Cardiovascular Disease	March 2009	Phase 4
NCT00571766	University of Modena and Reggio Emilia	Hypertension in Pregnancy	November 2007	Phase 3
NCT01841281	Nicholas Kenyon\|National Heart, Lung, and Blood Institute (NHLBI)\|University of California, Davis	Asthma\|Inflammation	August 2013	Phase 2
NCT02894723	Meir Medical Center	Hypertension	September 2016	Phase 4
NCT02536170	Emory University\|Children´s Healthcare of Atlanta\|National Center for Complementary and Integrative Health (NCCIH)	Sickle Cell Disease\|Vaso-occlusive Pain Episode	February 2016	Phase 2
NCT00603720	Washington University School of Medicine\|National Institute on Aging (NIA)	Cardiovascular Diseases	September 2005	Not Applicable
NCT01388764	Massachusetts General Hospital	Dystrophinopathy\|Duchenne Muscular Dystrophy\|Becker´s Muscular Dystrophy	January 2012	Phase 1
NCT00777075	Hannover Medical School\|Pharmacia	Erectile Dysfunction	July 2003	Phase 4
NCT00587418	Mayo Clinic\|National Center for Complementary and Integrative Health (NCCIH)	Liver Transplant Recipients	November 2008	Not Applicable
NCT01603446	The Hospital for Sick Children	MELAS Syndrome	May 2012	Phase 2
NCT04112875	Rio de Janeiro State University\|Laboratory for Clinical and Experimental Research on Vascular Biology	Aging\|Sarcopenia\|Type 2 Diabetes\|Microcirculation	April 2016	Not Applicable
NCT01439555	University of Massachusetts, Worcester\|The Glass Foundation	Alzheimer´s Disease	November 2011	Phase 2
NCT00134433	Ottawa Heart Institute Research Corporation\|Heart and Stroke Foundation of Ontario	Coronary Artery Disease	November 2004	Phase 1\|Phase 2
NCT00551434	Boston University	Coronary Artery Disease	August 2002	Not Applicable
NCT00583388	Mayo Clinic	Healthy	June 2010
NCT01485757	University of Michigan	Heart Transplant	July 2011	Phase 1
NCT01105130	Wake Forest University Health Sciences\|National Cancer Institute (NCI)	Male Erectile Disorder\|Prostate Cancer\|Radiation Toxicity	October 1, 2010	Phase 2
NCT03827005	North Dakota State University	Healthy Adult	July 16, 2016	Not Applicable
NCT04765644	Imperial College London	Healthy	June 10, 2021	Phase 4
NCT05470998	Tanta University	Sickle Cell Disease	November 25, 2021	Phase 3
NCT01775020	Maastricht University Medical Center\|Novartis Medical Nutrition	Sepsis\|Septic Shock	October 2003	Early Phase 1
NCT01482247	Brigham and Women´s Hospital	Hypertension\|Diabetes	April 2012	Phase 2
NCT00917449	IRCCS San Raffaele	Metabolic Syndrome\|Impaired Glucose Tolerance\|Insulin Resistance\|Endothelial Dysfunction	December 2005	Phase 3
NCT03834610	Aswan University Hospital	Erectile Dysfunction	October 1, 2017	Not Applicable
NCT00001752	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Hypercholesterolemia\|Postmenopause	September 1998	Phase 2
NCT05042024	Ukrainian Medical Stomatological Academy	Periodontitis	October 20, 2017	Phase 3
NCT04239482	Maastricht University Medical Center\|Nutricia Research	Nitric Oxide\|Insulin Sensitivity\|Vascular Function\|L-arginine\|Nitrate + Nitrite	September 1, 2020	Not Applicable
NCT01263041	Ain Shams University	NEC\|Sepsis	May 2011	Phase 2\|Phase 3
NCT02844387	Instituto de Oncología �ngel H. Roffo	Unresectable Multiple Brain Metastases	May 2004	Phase 1\|Phase 2
NCT02291458	Maastricht University Medical Center\|Leiden University Medical Center	Adipose Tissue, Brown\|Glucose Intolerance\|Nitric Oxide	November 2014	Phase 3
NCT05281562	Prisma Health-Midlands	Diabetes Mellitus\|Diabetic Peripheral Neuropathy\|Diabetic Foot Ulcer	October 2022	Phase 2\|Phase 3
NCT00785811	Sanofi	Muscular Fatigue	October 2008	Phase 4
NCT00284076	Stanford University\|National Heart, Lung, and Blood Institute (NHLBI)	Cardiovascular Diseases\|Peripheral Vascular Diseases	February 2000	Not Applicable
NCT00223717	Vanderbilt University\|Vanderbilt University Medical Center	Hypertension	January 2001	Phase 1
NCT00157521	Mario Negri Institute for Pharmacological Research	Pre-Eclampsia	September 2002	Phase 3
NCT00275158	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\|National Center for Research Resources (NCRR)	Pre-Eclampsia	January 2000	Not Applicable
NCT04475861	Chang Gung Memorial Hospital\|Ministry of Science and Technology, Taiwan	Diabetes Mellitus, Type 2\|Infection	October 31, 2018	Not Applicable
NCT03861416	POLYSAN Scientific & Technological Pharmaceutical Company	Peripheral Arterial Disease	March 16, 2018	Phase 2
NCT04701463	Azienda di Servizi alla Persona di Pavia	Amino Acid\|Body Weight Changes\|Skin Manifestations\|Obesity\|Postmenopausal Disorder	January 15, 2020	Not Applicable
NCT03665116	Memorial University of Newfoundland\|Ocean Frontier Institute	Knee Osteoarthritis	March 5, 2019	Not Applicable
NCT02838030	University of Guadalajara\|PhD Ernesto Javier Ramírez Lizardo\|PhD Sylvia Elena Totsuka Sutto\|PhD Fernando Grover Páez\|MD Diego Hernández Molina	High Risk Pregnancy	July 1, 2018	Phase 2
NCT00213915	University Hospital, Strasbourg, France	Heart Transplantation	February 2004	Phase 4
NCT04535427	RenJi Hospital	Rheumatoid Arthritis	January 1, 2021	Phase 2
NCT00280683	University of California, Davis\|National Institutes of Health (NIH)\|National Center for Research Resources (NCRR)	Asthma	December 2004	Phase 2
NCT03402191	Sherief Abd-Elsalam\|Tanta University	Thalassemia	July 2016	Phase 4
NCT00974714	University of Modena and Reggio Emilia\|University of Modena	Hypertension in Pregnancy	September 2007	Phase 3
NCT03625596	Maastricht University Medical Center\|Nutricia Research	Nitric Oxide\|Vascular Function\|L-Arginine\|Nitrate + Nitrite\|Postprandial Metabolism	December 1, 2018	Not Applicable
NCT01855334	Brigham and Women´s Hospital\|Massachusetts General Hospital\|Beth Israel Deaconess Medical Center\|Joslin Diabetes Center	End Stage Renal Disease\|Hemodialysis	September 2013	Phase 4
NCT03982160	The University of Texas at Arlington	Chronic Kidney Disease	February 1, 2018	Phase 4
NCT04800692	Louis Messina\|BioMarin Pharmaceutical\|University of Massachusetts, Worcester	Claudication, Intermittent\|Peripheral Artery Disease\|Peripheral Vascular Diseases	June 15, 2021	Phase 1
NCT03378596	Juliano Casonatto\|Universidade Norte do Paraná	Hypertension	January 2, 2018	Not Applicable
NCT00616304	Menzies School of Health Research\|Wellcome Trust\|National Health and Medical Research Council, Australia	Severe Falciparum Malaria	February 2008	Phase 2
NCT00405665	The Hospital for Sick Children	Cystic Fibrosis	November 2006	Phase 2
NCT01038622	Assistance Publique - Hôpitaux de Paris	Critically Ill	November 2009	Phase 4
NCT01326416	University Hospital, Rouen	Obesity\|Metabolic Syndrome	March 2011	Not Applicable
NCT02516085	University Hospital, Basel, Switzerland	Duchenne Muscular Dystrophy	January 2012	Phase 1
NCT00902616	Tameside Hospital NHS Foundation Trust	Type 2 Diabetes	June 2003	Phase 4
NCT01142219	Hospital de Clinicas de Porto Alegre\|Fundo de Incentivo à Pesquisa do Hospital de Clinicas de Porto Alegre (FIPE)\|Associação de Amigos da Hematologia (HEMOAMIGOS)\|Ajinomoto Interamericana Indústria e Comércio Ltda. (donation of L-arginine)	Sickle Cell Disease	September 2006	Phase 3
NCT02398279	Hacettepe University	Schizophrenia\|Schizoaffective Disorder	June 2011	Not Applicable
NCT03679780	The University of Texas at Arlington	Cardiovascular Diseases\|Cardiovascular Risk Factor\|Vasoconstriction	October 1, 2018	Phase 1
NCT02850367	University Hospital, Grenoble	Physiology	May 9, 2016	Not Applicable
NCT00056433	National Institutes of Health Clinical Center (CC)	Sickle Cell Anemia	March 10, 2003	Phase 1
NCT00051376	National Heart, Lung, and Blood Institute (NHLBI)	Myocardial Infarction	September 2001	Not Applicable
NCT01742702	Tampere University\|Finnish Foundation for Cardiovascular Research\|Paavo Nurmi Foundation\|Sigrid Jusélius Foundation\|Finnish Cultural Foundation\|Tampere Tuberculosis Foundation\|Medical Research Fund of the Tampere University Hospital, Finland\|Aarne Koskelo Foundation\|Finnish Medical Foundation\|Finnish Kidney Foundation\|Päivikki and Sakari Sohlberg Foundation, Finland	Primary Hypertension\|Secondary Hypertension\|Aortic Stenosis\|Renal Insufficiency	May 25, 2006

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

H ₂ O : 50 mg/mL ( 287.03 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	5.7405 mL	28.7026 mL	57.4053 mL
5 mM	1.1481 mL	5.7405 mL	11.4811 mL
10 mM	0.5741 mL	2.8703 mL	5.7405 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 100 mg/mL (574.05 mM); Clear solution; Need ultrasonic

* All of the co-solvents are available by MCE.

References

Synonyms

L-Arginine

Arginine, L-

Arginine

Pentanoic acid, 2-amino-5-[(aminoiminomethyl)amino]-, (S)-

L-(+)-Arginine

(S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid

L-Norvaline, 5-[(aminoiminomethyl)amino]-

L-Ornithine, N⁵-(aminoiminomethyl)-

L-α-Amino-δ-guanidinovaleric acid

L-Arg

NSC 206269

L-arginine C Grade

A 0526

(2S)-2-Amino-5-(diaminomethylideneamino)pentanoic acid

42: PN: WO2020027640 SEQID: 105 claimed protein

42: PN: KR20200014684 SEQID: 105 claimed sequence

117: PN: WO2021061872 SEQID: 117 claimed protein